相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The COMT Val158Met Polymorphism Affects the Response to Entacapone in Parkinson's Disease: A Randomized Crossover Clinical Trial
Jean-Christophe Corvol et al.
ANNALS OF NEUROLOGY (2011)
Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population
Takeshi Ozeki et al.
HUMAN MOLECULAR GENETICS (2011)
Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan
Pei Chen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans
Mark McCormack et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Increased Risk of Vincristine Neurotoxicity Associated With Low CYP3A5 Expression Genotype in Children With Acute Lymphoblastic Leukemia
Akinbode Egbelakin et al.
PEDIATRIC BLOOD & CANCER (2011)
Acceptance of Biomarker-Based Tests for Application in Clinical Practice: Criteria and Obstacles
M. Pirmohamed
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Effects of Donepezil, Galantamine and Rivastigmine in 938 Italian Patients with Alzheimer's Disease A Prospective, Observational Study
Aurelia Santoro et al.
CNS DRUGS (2010)
Predisposition to epilepsy-Does the ABCB1 gene play a role?
Laila Nurmohamed et al.
EPILEPSIA (2010)
Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741
Howard L. McLeod et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Warfarin Genotyping Reduces Hospitalization Rates Results From the MM-WES (Medco-Mayo Warfarin Effectiveness Study)
Robert S. Epstein et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration A Systematic Meta-Analysis
Jean-Sebastien Hulot et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Prediction of the warfarin maintenance dose after completion of the 10 mg initiation nomogram: do we really need genotyping?
G. Le Gal et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment
Guillaume Pare et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future
Ana Alfirevic et al.
PHARMACOGENOMICS (2010)
The Evolving Field of Stroke Prevention in Patients With Atrial Fibrillation
Michael D. Ezekowitz et al.
STROKE (2010)
Variability of AChE, BChE, and ChAT Genes in the Late-Onset Form of Alzheimer's Disease and Relationships With Response to Treatment With Donepezil and Rivastigmine
Renato Scacchi et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS (2009)
Genome-wide Scan of 500 000 Single-Nucleotide Polymorphisms Among Responders and Nonresponders to Interferon Beta Therapy in Multiple Sclerosis
Manuel Comabella et al.
ARCHIVES OF NEUROLOGY (2009)
ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis
S. Cotte et al.
BRAIN (2009)
Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients
Ying-Zi Liu et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain
David Gurwitz et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2009)
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
Alan R. Shuldiner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Pharmacogenetic Analyses of a Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma With Fluorouracil and Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
Eray Goekkurt et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Platinum neurotoxicity pharmacogenetics
Sarah R. McWhinney et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Diagnosis, natural history, and management of Charcot-Marie-Tooth disease
Davide Pareyson et al.
LANCET NEUROLOGY (2009)
Glypican 5 is an interferon-beta response gene: a replication study
M. D. C. Cenit et al.
MULTIPLE SCLEROSIS JOURNAL (2009)
SEVERE CARDIAC FAILURE IN A PATIENT WITH MULTIPLE SCLEROSIS FOLLOWING LOW-DOSE MITOXANTRONE TREATMENT
J. Doerr et al.
NEUROLOGY (2009)
Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease
Alberto Pilotto et al.
NEUROLOGY (2009)
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
S. Salloway et al.
NEUROLOGY (2009)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Genetic polymorphisms, their allele combinations and IFN-β treatment response in Irish multiple sclerosis patients
Catherine O'Doherty et al.
PHARMACOGENOMICS (2009)
HLA-DRBI*0401 and HLA-DRBI*0408 are strongly associated with the development of antibodies against interferon-β therapy in multiple sclerosis
Steve Hoffmann et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2008)
Genome-wide pharmacogenomic analysis of the response to interferon β therapy in multiple sclerosis
Esther Byun et al.
ARCHIVES OF NEUROLOGY (2008)
Pharmacology and management of the vitamin K antagonists
Jack Ansell et al.
CHEST (2008)
Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease
Seong Hye Choi et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2008)
Pharmacological treatment of early multiple sclerosis
Olaf Stueve et al.
DRUGS (2008)
Immunosuppression in clinical practice Approaches to individualized therapy
Andrew Chan et al.
JOURNAL OF NEUROLOGY (2008)
Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations
H. Wiendl et al.
JOURNAL OF NEUROLOGY (2008)
The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease
Sebastian Paus et al.
MOVEMENT DISORDERS (2008)
Tacrine-induced liver damage: an analysis of 19 candidate genes
Ana Alfirevic et al.
PHARMACOGENETICS AND GENOMICS (2007)
Predictive factors of oxaliplatin neurotoxicity: The involvement of the oxalate outcome pathway
Laurence Gamelin et al.
CLINICAL CANCER RESEARCH (2007)
Thiopurine-S-methyltransferase genotype and the response to azathioprine in inflammatory bowel disease
G. Stocco et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
G protein β3 polymorphism and triptan response in cluster headache
M. Schuerks et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?
Muin J. Khoury et al.
GENETICS IN MEDICINE (2007)
Repair capacity for Platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy
Anna Dzagnidze et al.
JOURNAL OF NEUROSCIENCE (2007)
Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers
Iris Grossman et al.
PHARMACOGENETICS AND GENOMICS (2007)
A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer
Taisuke Mori et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2007)
ABCB1 genotype and PGP expression, function and therapeutic drug response:: a critical review and recommendations for future research
G. D. Leschziner et al.
PHARMACOGENOMICS JOURNAL (2007)
The Phe-124-Cys and A-161T variants of the human 5-HT1B receptor gene are not major determinants of the clinical response to sumatriptan
Suneet Mehrotra et al.
HEADACHE (2007)
The G1246A polymorphism in the hypocretin receptor 2 gene is not associated with treatment response in cluster headache
M. Schuerks et al.
CEPHALALGIA (2007)
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
Annamaria Ruzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease
Juei-Jueng Lin et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2007)
Pharmacogenetics of warfarin: current status and future challenges
M. Wadelius et al.
PHARMACOGENOMICS JOURNAL (2007)
Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease
Rafael Blesa et al.
PHARMACOGENETICS AND GENOMICS (2006)
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia
Tristan M. Sissung et al.
EUROPEAN JOURNAL OF CANCER (2006)
Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response:: a prospective cohort study
Guy Leschziner et al.
LANCET NEUROLOGY (2006)
Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy
Thierry Lecomte et al.
CLINICAL CANCER RESEARCH (2006)
Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease
Judith A. Strong et al.
MOVEMENT DISORDERS (2006)
An IFNG polymorphism is associated with interferon-beta response in Spanish MS patients
A Martínez et al.
JOURNAL OF NEUROIMMUNOLOGY (2006)
A single nucleotide polymorphism in CHAT influences response to acetylcholinesterase inhibitors in Alzheimer's disease
Denise Harold et al.
PHARMACOGENETICS AND GENOMICS (2006)
Genetic factors in the predisposition to drug-induced hypersensitivity reactions
M Pirmohamed
AAPS JOURNAL (2006)
Effect of the apolipoprotein E epsilon 4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease
GH Suh et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2006)
Apolipoprotein epsilon 4 advances appearance of psychosis in patients with Parkinson's disease
B Feldman et al.
ACTA NEUROLOGICA SCANDINAVICA (2006)
Pharmacogenomics of responsiveness to interferon IFN-β treatment in multiple sclerosis:: A genetic screen of 100 type I interferon-inducible genes
S Cunningham et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease
EK Tan et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS (2005)
Drug resistance in brain diseases and the role of drug efflux transporters
W Löscher et al.
NATURE REVIEWS NEUROSCIENCE (2005)
Vitamin E and donepezil for the treatment of mild cognitive impairment
RC Petersen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic -: Pharmacodynarnic pattern in patients with Parkinson's disease
M Contin et al.
MOVEMENT DISORDERS (2005)
IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis
S Wergeland et al.
EUROPEAN JOURNAL OF NEUROLOGY (2005)
Apolipoprotein E epsilon 4 allele differentiates the clinical response to donepezil in Alzheimer's disease
A Bizzarro et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2005)
Thiopurine S-methyltransferase polymorphisms:: efficient screening method for patients considering taking thiopurine drugs
B Wusk et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting sleep attacks
I Rissling et al.
MOVEMENT DISORDERS (2004)
Association study of dopamine D2, D3, D4 receptor and serotonin transporter gene polymorphisms with sleep attacks in Parkinson's disease
S Paus et al.
MOVEMENT DISORDERS (2004)
A polymorphism of the hypocretin receptor 2 gene is associated with cluster headache
I Rainero et al.
NEUROLOGY (2004)
The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease
M Bialecka et al.
ACTA NEUROLOGICA SCANDINAVICA (2004)
L-Dopa-induced adverse effects in PD and dopamine transporter gene polymorphism
R Kaiser et al.
NEUROLOGY (2003)
Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson's disease
J Wang et al.
PHARMACOGENETICS (2003)
Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1
A Siddiqui et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis
C Fusco et al.
NEUROLOGY (2001)
Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD
J Wang et al.
NEUROLOGY (2001)
Genetic variation analysis in Parkinson disease patients with and without hallucinations - Case-control study
CG Goetz et al.
ARCHIVES OF NEUROLOGY (2001)
Responder characteristics to a single oral dose of cholinesterase inhibitor: A double-blind placebo-controlled study with tacrine in Alzheimer patients
O Almkvist et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2001)
Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity
T Simon et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease
DJ Chong et al.
CLINICAL NEUROPHARMACOLOGY (2000)
Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease
AJ Makoff et al.
PHARMACOGENETICS (2000)
Donepezil therapy in clinical practice - A randomized crossover study
SM Greenberg et al.
ARCHIVES OF NEUROLOGY (2000)
分享论文
